DYN NASDAQ
Dyne Therapeutics, Inc.
1W: -5.0%
1M: -11.7%
3M: +16.7%
YTD: -6.1%
1Y: +40.8%
3Y: +30.1%
5Y: -0.6%
$17.37
+0.00 (+0.00%)
Weekly Expected Move ±7.8%
$15
$16
$17
$19
$20
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.72
Bullish
4 bullish
1 neutral
0 bearish
Articles (7d)
5
Daily Sentiment (7 Days)
Articles (58)
Dyne Stock Gains 10% on Initiation of Late-Stage Study in DMD Patients
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dyne spikes as late-stage trial for Duchenne therapy gets underway
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares
Dyne Therapeutics (DYN) Upgraded to Buy: Here's What You Should Know
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 73,108 Shares of Stock
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 137,948 Shares of Stock
Dyne Therapeutics (NASDAQ:DYN) Director Jason Rhodes Sells 173,493 Shares of Stock
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
Jason Rhodes Sells 272,049 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
Jason Rhodes Sells 274,297 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
Jason Rhodes Sells 287,956 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Darwin Wealth Management LLC Sells 58,250 Shares of Dyne Therapeutics, Inc. $DYN
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of “Moderate Buy” from Analysts
Dyne Therapeutics (NASDAQ:DYN) Stock Price Up 4.4% – Here’s Why
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co.
Revolution, Ascendis, Arrowhead among RBC’s top M&A candidates in biotech
HC Wainwright Lifts Earnings Estimates for Dyne Therapeutics
Equities Analysts Issue Forecasts for DYN Q1 Earnings
Lifesci Capital Has Bullish Estimate for DYN Q1 Earnings
Dyne Therapeutics (NASDAQ:DYN) Stock Price Down 6.6% on Disappointing Earnings
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
Dyne Therapeutics GAAP EPS of -$0.76 beats by $0.02
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Moderate Buy” by Analysts
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside?
Dyne Therapeutics: 2026 Catalysts Point To Further Upside
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN
Dyne Therapeutics, Inc. (DYN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Consensus Rating of “Moderate Buy” by Analysts
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
Why Dyne Therapeutics Stock Was a Big Winner on Wednesday
Dyne Therapeutics: Why The $350M Public Offering Was Critical
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock
Why Dyne Therapeutics Stock Tanked on Tuesday
Why a Biotech Fund Made Dyne Therapeutics One of Its Biggest Stock Bets
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
Why Dyne Therapeutics Stock Was Blasting Higher Today
Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript
Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?
Why Dyne Therapeutics Stock Was Crushing it This Week